Omeros (NASDAQ:OMER) VP Sells $466,250.00 in Stock

Omeros Corporation (NASDAQ:OMER) VP Peter Cancelmo sold 25,000 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $18.65, for a total value of $466,250.00. Following the completion of the transaction, the vice president directly owned 200 shares of the company’s stock, valued at approximately $3,730. This trade represents a 99.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Omeros Trading Down 0.2%

Shares of Omeros stock traded down $0.05 on Tuesday, hitting $19.39. 387,803 shares of the company traded hands, compared to its average volume of 1,687,194. The stock’s 50 day moving average price is $16.40 and its 200-day moving average price is $13.11. Omeros Corporation has a 52 week low of $4.05 and a 52 week high of $21.24. The company has a market cap of $1.40 billion, a PE ratio of 15.15 and a beta of 2.60.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. As a group, research analysts anticipate that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on OMER shares. Weiss Ratings cut shares of Omeros from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, September 22nd. Cantor Fitzgerald raised Omeros from a “neutral” rating to an “overweight” rating and set a $22.00 price target on the stock in a research report on Tuesday, September 22nd. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. HC Wainwright restated a “buy” rating on shares of Omeros in a report on Monday, July 27th. Finally, Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $34.00.

Institutional Trading of Omeros

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Omeros in the 2nd quarter worth approximately $57,484,000. UBS Group AG grew its position in Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after purchasing an additional 1,513,893 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after purchasing an additional 666,357 shares during the last quarter. Corient Private Wealth LP bought a new position in Omeros in the second quarter valued at about $6,274,000. Finally, State Street Corp grew its stake in Omeros by 20.9% in the second quarter. State Street Corp now owns 2,319,906 shares of the biopharmaceutical company’s stock valued at $22,062,000 after acquiring an additional 400,331 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.